Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer
Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effect taking cisplatin in combination with
bevacizumab before surgery and then standard chemotherapy plus bevacizumab after surgery will
have on participants with Estrogen Receptor (ER) negative, Progesterone Receptor (PR)
negative and Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer.
Cisplatin is used to destroy cancer cells in many types of cancers, and has shown to be
effective and have manageable side effects. Bevacizumab is an antibody, which is a protein
that attacks a foreign substance in the body. Bevacizumab slows or stops cell growth in
cancerous tumors by decreasing the blood supply to the tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Dana-Farber Cancer Institute Genentech, Inc.